Diabetic macular oedema

Diabetic macular oedema

In the RESTORE extension study, Prof Paolo Lanzetta from the Department of Ophthalmology, University of Udine introduced results from 240 patients with diabetic macular oedema (DME) who received individualised treatment with ranibizumab in a regimen consistent with the European Union label, the standard of care in wet AMD. The data presented at the 12th EURETINA Congress in Milan, Italy, showed that patients who were originally treated with ranibizumab received an average of 13.9 injections over three years. The mean of seven letters of visual acuity gained in the RESTORE core study were maintained with an average of 3.7 injections in the second year and 2.7 in the third year. 

Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...